Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Allogene anti-CD19 CAR-T-celtherapie voor gerecidiveerde of refractaire B-cel ALL
dec 2022 | Leukemie